[{"id":"a9b3c781-9089-4a7a-b7a8-a636626ceef3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05741021","created_at":"2023-02-23T15:01:10.118Z","updated_at":"2024-07-02T16:35:54.750Z","phase":"Phase 2","brief_title":"A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05741021","lead_sponsor":"Shandong New Time Pharmaceutical Co., LTD","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • pemetrexed • rulonilimab (F520)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 10/25/2024","primary_completion_date":" 10/25/2024","study_txt":" Completion: 10/25/2024","study_completion_date":" 10/25/2024","last_update_posted":"2023-02-24"},{"id":"263d27c9-8ad3-411d-b439-1668ecef73b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05178836","created_at":"2022-01-05T12:53:43.497Z","updated_at":"2024-07-02T16:36:18.826Z","phase":"Phase 2","brief_title":"A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL","source_id_and_acronym":"NCT05178836","lead_sponsor":"Shandong New Time Pharmaceutical Co., LTD","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e F007 (rituximab biosimilar) • rulonilimab (F520)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-01-05"},{"id":"0726687c-fecd-4fe5-aeda-ca45e3a33859","acronym":"","url":"https://clinicaltrials.gov/study/NCT03657381","created_at":"2021-01-18T17:56:58.616Z","updated_at":"2024-07-02T16:36:39.748Z","phase":"Phase 1","brief_title":"Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520","source_id_and_acronym":"NCT03657381","lead_sponsor":"Shandong New Time Pharmaceutical Co., LTD","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rulonilimab (F520)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 02/08/2021","primary_completion_date":" 02/08/2021","study_txt":" Completion: 10/08/2022","study_completion_date":" 10/08/2022","last_update_posted":"2020-10-22"},{"id":"113fe0e2-bcee-4cdd-91e9-365db58ea65d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04457830","created_at":"2021-01-18T21:26:15.885Z","updated_at":"2024-07-02T16:36:39.826Z","phase":"Phase 2","brief_title":"The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).","source_id_and_acronym":"NCT04457830","lead_sponsor":"Shandong New Time Pharmaceutical Co., LTD","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rulonilimab (F520)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 11/01/2020","start_date":" 11/01/2020","primary_txt":" Primary completion: 07/31/2022","primary_completion_date":" 07/31/2022","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2020-10-21"}]